Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia.

Gandhi S, Kulasekararaj AG, Mufti GJ, Marsh JC.

Int J Hematol. 2013 May;97(5):573-80. doi: 10.1007/s12185-013-1333-9. Epub 2013 Apr 30. Review.

PMID:
23632948
2.

Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells.

Grimaldi F, Potter V, Perez-Abellan P, Veluchamy JP, Atif M, Grain R, Sen M, Best S, Lea N, Rice C, Pagliuca A, Mufti GJ, Marsh JCW, Barber LD.

Biol Blood Marrow Transplant. 2017 Feb;23(2):293-299. doi: 10.1016/j.bbmt.2016.11.003. Epub 2016 Nov 2.

3.

Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis.

Busemann C, Neumann T, Schulze M, Klenner A, Thiele T, Greinacher A, Dölken G, Krüger WH.

Ann Hematol. 2013 Jul;92(7):945-52. doi: 10.1007/s00277-013-1714-4. Epub 2013 Mar 5.

PMID:
23463451
4.

Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia.

Marsh JC, Gupta V, Lim Z, Ho AY, Ireland RM, Hayden J, Potter V, Koh MB, Islam MS, Russell N, Marks DI, Mufti GJ, Pagliuca A.

Blood. 2011 Aug 25;118(8):2351-7. doi: 10.1182/blood-2010-12-327536. Epub 2011 Apr 25.

5.

Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia.

Gupta V, Ball SE, Yi QL, Sage D, McCann SR, Lawler M, Ortin M, Freires M, Hale G, Waldmann H, Gordon-Smith EC, Marsh JC.

Biol Blood Marrow Transplant. 2004 Dec;10(12):867-76.

6.

Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.

Hsieh MM, Fitzhugh CD, Weitzel RP, Link ME, Coles WA, Zhao X, Rodgers GP, Powell JD, Tisdale JF.

JAMA. 2014 Jul 2;312(1):48-56. doi: 10.1001/jama.2014.7192.

7.
8.

In vivo T-cell depletion using alemtuzumab in family and unrelated donor transplantation for pediatric non-malignant disease achieves engraftment with low incidence of graft vs. host disease.

Saif MA, Borrill R, Bigger BW, Lee H, Logan A, Poulton K, Hughes S, Turner AJ, Bonney DK, Wynn RF.

Pediatr Transplant. 2015 Mar;19(2):211-8. doi: 10.1111/petr.12416. Epub 2014 Dec 26.

PMID:
25546609
9.

Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study.

Straathof KC, Rao K, Eyrich M, Hale G, Bird P, Berrie E, Brown L, Adams S, Schlegel PG, Goulden N, Gaspar HB, Gennery AR, Landais P, Davies EG, Brenner MK, Veys PA, Amrolia PJ.

Lancet. 2009 Sep 12;374(9693):912-20. doi: 10.1016/S0140-6736(09)60945-4. Epub 2009 Sep 2.

PMID:
19729196
10.

Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia.

Kennedy-Nasser AA, Leung KS, Mahajan A, Weiss HL, Arce JA, Gottschalk S, Carrum G, Khan SP, Heslop HE, Brenner MK, Bollard CM, Krance RA.

Biol Blood Marrow Transplant. 2006 Dec;12(12):1277-84.

12.

Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation.

Marsh JC, Pearce RM, Koh MB, Lim Z, Pagliuca A, Mufti GJ, Perry J, Snowden JA, Vora AJ, Wynn RT, Russell N, Gibson B, Gilleece M, Milligan D, Veys P, Samarasinghe S, McMullin M, Kirkland K, Cook G; British Society for Blood and Marrow Transplantation, Clinical Trials Committee.

Bone Marrow Transplant. 2014 Jan;49(1):42-8. doi: 10.1038/bmt.2013.115. Epub 2013 Aug 5.

PMID:
23912664
13.

In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantation.

Kanda Y, Oshima K, Kako S, Fukuda T, Uchida N, Miyamura K, Kondo Y, Nakao S, Nagafuji K, Miyamoto T, Kurokawa M, Okoshi Y, Chiba S, Ohashi Y, Takaue Y, Taniguchi S.

Am J Hematol. 2013 Apr;88(4):294-300. doi: 10.1002/ajh.23392. Epub 2013 Feb 28.

14.

Allogeneic transplantation using CD34+ selected peripheral blood progenitor cells combined with non-mobilized donor T cells for refractory severe aplastic anaemia.

Purev E, Tian X, Aue G, Pantin J, Vo P, Shalabi R, Reger RN, Cook L, Ramos C, Cho E, Worthy T, Khuu H, Stroncek D, Young NS, Childs RW.

Br J Haematol. 2017 Mar;176(6):950-960. doi: 10.1111/bjh.14448. Epub 2017 Feb 7.

PMID:
28169418
15.

Cotransplantation of bone marrow-derived mesenchymal stem cells in haploidentical hematopoietic stem cell transplantation in patients with severe aplastic anemia: an interim summary for a multicenter phase II trial results.

Liu Z, Zhang Y, Xiao H, Yao Z, Zhang H, Liu Q, Wu B, Nie D, Li Y, Pang Y, Fan Z, Li L, Jiang Z, Duan F, Li H, Zhang P, Gao Y, Ouyang L, Yue C, Xie M, Shi C, Xiao Y, Wang S.

Bone Marrow Transplant. 2017 May;52(5):704-710. doi: 10.1038/bmt.2016.347. Epub 2017 Jan 9. Erratum in: Bone Marrow Transplant. 2017 Jul;52(7):1080.

PMID:
28067873
16.

[A comparative study of unrelated donor and matched-sibling donor allogeneic hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia].

Zhou J, Fu YW, Liang LJ, Wang Q, Han LJ, Zu YL, Zhang Y, Zhu XH, Yu FK, Fang BJ, Wei XD, Song YP.

Zhonghua Nei Ke Za Zhi. 2016 Dec 1;55(12):927-931. doi: 10.3760/cma.j.issn.0578-1426.2016.12.004. Chinese.

PMID:
27916046
17.

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders.

Pérez-Simón JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, García-Conde J, Milligan DW, Schey S, Urbano-Ispizua A, Parker A, Leon A, Yong K, Sureda A, Hunter A, Sierra J, Goldstone AH, Linch DC, San Miguel JF, Mackinnon S; Spanish and United Kingdom Collaborative Groups for Nonmyeloablative Transplantation.

Blood. 2002 Nov 1;100(9):3121-7.

18.

Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA.

Lawler M, McCann SR, Marsh JC, Ljungman P, Hows J, Vandenberghe E, O'Riordan J, Locasciulli A, Socié G, Kelly A, Schrezenmeier H, Marin P, Tichelli A, Passweg JR, Dickenson A, Ryan J, Bacigalupo A; Severe Aplastic Anaemia Working Party of the European Blood and Marrow Transplant Group.

Br J Haematol. 2009 Mar;144(6):933-45. doi: 10.1111/j.1365-2141.2008.07533.x. Epub 2009 Jan 9.

PMID:
19183198
19.

Analysis of allogeneic hematopoietic stem cell transplantation with high-dose cyclophosphamide-induced immune tolerance for severe aplastic anemia.

Guo Z, Gao HY, Zhang TY, Liu XD, Yang K, Lou JX, He XP, Zhang Y, Chen P, Chen HR.

Int J Hematol. 2016 Dec;104(6):720-728. Epub 2016 Oct 5.

PMID:
27709450
20.

Supplemental Content

Support Center